SOUTHLAKE, Texas, July 11, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic […]
Tag: RBT-1
Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American Association for Thoracic Surgery (AATS) Meeting
RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery– RBT-1 as a preconditioning agent has the potential to provide patient benefits in multiple surgical settings where organ injury during surgery increases […]
Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial
-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery- –RBT-1 treatment demonstrated a reduction in time on ventilator, ICU days, length of hospital stay and 30-day hospital readmission rates- –Planned pivotal Phase […]
Renibus Therapeutics Presents Interim Phase 2 Data: RBT-1 Improves Post-Operative Outcomes in Cardiac Surgery Patients During Oral Session at AHA Scientific Sessions 2022
-RBT-1 interim results from a randomized double-blind placebo-controlled study showed statistically significant reductions in days on ventilator and days in ICU. 30-day hospital readmission was reduced by greater than 90% -(<0.0027)- -RBT-1 was recently granted Fast Track Designation from U.S. FDA- -Pivotal Phase 3 study of RBT-1 to be initiated […]
Recent
RamSoft and CARPL.ai Announce Partnership and Integration to Enhance RamSoft’s AI Offering
Dr. Curtis Langlotz Joins Sirona Medical’s Board
Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Popular
- No commented posts yet